CT, Capital Trust, Inc.
** CT reported that its Board of Directors has formed a Special Committee of the Board comprised of independent directors (the "Special Committee") to consider and explore strategic alternatives available to CT in order to maximize shareholder value.
The Special Committee intends to undertake a thorough exploration of the full range of alternatives, including a possible sale of CT and has retained Evercore Partners to serve as its financial advisor.
No decision has been made to engage in a transaction or transactions resulting from the Special Committee's exploration of strategic alternatives. There can be no assurance that that the Special Committee or the Board will authorize the pursuit of any strategic alternative. Moreover, there can be no assurance with respect to the terms or the timing of any transaction, or whether a transaction will ultimately result at all.
CT is a fully integrated, self-managed real estate finance and investment management company that specializes in credit sensitive structured financial products. To date, CT's investment programs have focused primarily on loans and securities backed by commercial real estate assets, investing both for its balance sheet and for third party vehicles.
More about CT at www.capitaltrust.com
CDXS, Codexis, Inc.
** CDXS reported that the U.S Patent and Trademark Office (USPTO) has granted CDXS? patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The patent is titled ?BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS? and was issued as U.S. patent number 8,178,333. The 20-year term of this patent does not expire until 2029.
This patent follows a recently published article in the Journal of the American Chemical Society (JACS) that discusses collaborative research conducted by Merck and CDXS scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir (www.pubs.acs.org/doi/pdf/10.1021/ja3010495).
CDXS is a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates.
More about CDXS at www.codexis.com.
USHS, U.S. Home Systems Inc.
** For the first quarter 2012, USHS posted revenue of $42.2 million, an 8.3% increase year over year, and net income of $853,000, or diluted EPS of $0.11, compared to net income of $560,000, or diluted EPS of $0.08 in the same period the prior year.
USHS manufactures or procures, designs, sells and installs custom quality specialty home improvement products. USHS' product lines include kitchen cabinet refacing products utilized in kitchen remodeling, bathroom tub liners and wall surround products utilized in bathroom remodeling, and storage organization systems for closets and garages.
More about USHS at at www.ushomesystems.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.